Lipid Metabolism Practice Questions

Q: All are true about beta oxidation of fatty acids except which of the following?

Carnitine Acyl transferase I is stimulated by malonyl CoA. ***Carnitine Acyl transferase I is stimulated by malonyl CoA*** - Malonyl CoA is a key intermediate in **fatty acid synthesis** and acts as an **inhibitor** of carnitine acyltransferase I (CAT1), not a stimulator. - This inhibition ensures that when fatty acid synthesis is active, fatty acid oxidation is suppressed, preventing a futile cycle. *Carnitine acyl transferase I is the rate limiting enzyme of fatty acid oxidation* - **Carnitine palmitoyltransferase 1 (CPT1)**, also known as carnitine acyltransferase I, is indeed the **rate-limiting step** for long-chain fatty acid entry into the mitochondrial matrix for beta-oxidation. - This enzyme controls the transport of fatty acyl-CoA into the mitochondria, which is essential for its subsequent breakdown. *Carnitine acyl transferase I is inhibited by malonyl CoA.* - **Malonyl CoA**, a precursor in fatty acid synthesis, serves as an allosteric inhibitor of **CAT1**. - This mechanism ensures that when the cell is actively synthesizing fatty acids, it simultaneously prevents their breakdown, helping to regulate overall energy metabolism. *Carnitine Acyl transferase I defect causes a decrease in acylcarnitine levels* - A defect in **CAT1** means fatty acids cannot be efficiently transported into the mitochondria to be converted into acylcarnitine for transport. - This leads to an accumulation of **free fatty acids** in the cytoplasm and a **decrease in acylcarnitine levels** in the blood and tissues, which can be used diagnostically.

Q: Arachidonic acid oxidation involves how many cycles of beta oxidation?

9. ***Correct Answer: 9*** - **Arachidonic acid** is a 20-carbon fatty acid (C20:4). For a fatty acid with *n* carbons, the number of beta-oxidation cycles required is **(n/2) - 1**. - Therefore, for **arachidonic acid** (n=20), the number of beta-oxidation cycles is (20/2) - 1, which equals 10 - 1 = **9 cycles**. - Each cycle removes 2 carbons as acetyl-CoA, shortening the fatty acid chain progressively. *Incorrect Option: 10* - This number represents the total number of **acetyl-CoA** molecules generated from a 20-carbon fatty acid, not the number of beta-oxidation cycles. - Each beta-oxidation cycle produces one **acetyl-CoA** and reduces the fatty acid chain by two carbons; the last cycle yields two **acetyl-CoA** molecules directly. *Incorrect Option: 20* - This value corresponds to the total number of carbons in **arachidonic acid**, not the number of beta-oxidation cycles. - The number of beta-oxidation cycles is significantly less than the total carbon count. *Incorrect Option: 8* - This number would be correct for an 18-carbon fatty acid like **stearic acid** (18/2 - 1 = 8), not for **arachidonic acid**. - The calculation explicitly depends on the exact number of carbon atoms in the fatty acid chain.

Q: Refsum's disease is due to deficiency of which of the following enzyme?

Phytanic alpha oxidase. ***Phytanic alpha oxidase*** - **Refsum's disease** is an **autosomal recessive peroxisomal disorder** characterized by the accumulation of **phytanic acid**. - This accumulation occurs due to the deficiency of **phytanic acid alpha-oxidase**, an enzyme crucial for the **alpha-oxidation** of branched-chain fatty acids. *Malonate dehydrogenase* - This enzyme is involved in the metabolism of **malonate**, typically oxidizing it to **malonyl-CoA**. - Its deficiency is not associated with Refsum's disease or the accumulation of phytanic acid. *Thiophorase* - Also known as **succinyl-CoA:3-ketoacid CoA transferase**, thiophorase is involved in **ketone body metabolism**. - Its deficiency leads to **succinyl-CoA:3-ketoacid CoA transferase deficiency**, causing **ketoacidosis**, not Refsum's disease. *Succinate thiokinase* - Also known as **succinyl-CoA synthetase**, this enzyme plays a role in the **Krebs cycle**, converting **succinyl-CoA to succinate**. - Its deficiency is a rare metabolic disorder presenting with **encephalopathy and lactic acidosis**, unrelated to phytanic acid metabolism.

Q: Which of the following conditions is characterized by a lack of genetically mediated VLDL overproduction?

Hypoapobetalipoproteinemia. ***Hypoapobetalipoproteinemia*** - This condition is characterized by **reduced production of apolipoprotein B**, leading to abnormally low levels of **VLDL and LDL** in the blood due to genetic mutations affecting apolipoprotein B synthesis or secretion. - Unlike the other options, it explicitly involves a *lack* of VLDL overproduction, making it the correct answer. *Familial combined hyperlipidemia* - This is a common genetic disorder characterized by **overproduction of VLDL** and occasionally decreased clearance of LDL, leading to elevated total cholesterol and triglycerides. - Patients often present with **elevated LDL and VLDL levels**, directly contradicting a lack of VLDL overproduction. *Familial dyslipidemic hypertension* - This condition is associated with a cluster of metabolic abnormalities, including **elevated triglycerides** (often secondary to VLDL overproduction) and hypertension. - The dyslipidemia component involves **increased VLDL production**, contributing to hypertriglyceridemia, rather than a lack of it. *LDL subclass B* - Refers to a predominance of **small, dense LDL particles**, which are more atherogenic than large, buoyant LDL particles. - The presence of small, dense LDL is often associated with conditions like **hypertriglyceridemia** and **insulin resistance**, which can be driven by increased VLDL production, not a lack thereof.

Q: In congenital adrenal hyperplasia, which enzyme deficiency is primarily responsible for precocious puberty in males?

21-hydroxylase deficiency. ***21-hydroxylase deficiency*** - This is the **most common form** of congenital adrenal hyperplasia (CAH) and leads to a **deficiency in cortisol and aldosterone** production [1]. - The accumulation of precursors shunts metabolic pathways towards **androgen production**, causing precocious puberty in males due to **excessive adrenal androgens** [1]. *11-beta-hydroxylase deficiency* - This deficiency also leads to **decreased cortisol** and an accumulation of precursors, but it specifically causes an increase in **deoxycorticosterone (DOC)**, which has mineralocorticoid activity. - While it also causes **androgen excess** (leading to precocious puberty in males), it is **less common** than 21-hydroxylase deficiency as the primary cause. *Both* - While both deficiencies can cause androgen excess and precocious puberty, **21-hydroxylase deficiency** is by far the more frequent and significant cause of these symptoms in CAH. - Attributing it equally to both would overlook the **prevalence** and primary impact of 21-hydroxylase deficiency. *Neither* - This option is incorrect because both 21-hydroxylase deficiency and 11-beta-hydroxylase deficiency can lead to **androgen excess**, which is the underlying cause of precocious puberty in CAH. - The condition is characterized by a defect in steroid synthesis, which inevitably results in a **hormonal imbalance**.

Q: Rate limiting step in fatty acid synthesis is?

Production of malonyl-CoA. ***Production of malonyl-CoA*** - The conversion of **acetyl-CoA to malonyl-CoA** is catalyzed by **acetyl-CoA carboxylase (ACC)**, which is the **rate-limiting enzyme** in fatty acid synthesis. - This step is highly regulated by **hormones** (e.g., insulin activates, glucagon inactivates) and **nutrient availability**, controlling the overall flux of fatty acid production. *Production of acetyl CoA* - While **acetyl-CoA** is the precursor for fatty acid synthesis, its production (e.g., from glycolysis via pyruvate dehydrogenase) is not the rate-limiting step for the synthesis pathway itself. - The availability of **acetyl-CoA** influences the pathway, but the committed step occurs later. *Production of oxaloacetate* - **Oxaloacetate** is primarily involved in the **citric acid cycle** and gluconeogenesis, and its production is not directly the rate-limiting step in fatty acid synthesis. - It combines with acetyl-CoA to form citrate, allowing acetyl-CoA to be shuttled out of the mitochondria. *Production of citrate* - **Citrate** is formed when **acetyl-CoA and oxaloacetate** combine in the mitochondria and is then transported to the cytoplasm to provide acetyl-CoA for fatty acid synthesis. - Although the availability of **cytoplasmic citrate** is important as a precursor for cytoplasmic acetyl-CoA and an allosteric activator of ACC, its production is not the rate-limiting step of fatty acid synthesis itself.

Q: Oxidation of very long chain fatty acids takes place in ?

Peroxisomes. ***Peroxisomes (Correct)*** - **Very long chain fatty acids (VLCFAs)**, which have more than 20 carbon atoms, undergo initial **beta-oxidation** in peroxisomes. - This process shortens the VLCFAs before they are transported to mitochondria for further oxidation. - Peroxisomes are essential for breaking down these fatty acids that are too long for direct mitochondrial processing. *Cytosol (Incorrect)* - The cytosol is the site for **fatty acid synthesis**, not oxidation. - It also plays a role in the initial steps of **glycerol phosphorylation** in triglyceride synthesis. *Mitochondria (Incorrect)* - **Mitochondria** primarily handle the beta-oxidation of **medium and short-chain fatty acids** (typically less than 20 carbons). - While VLCFAs are eventually oxidized here after peroxisomal shortening, their initial breakdown must occur in peroxisomes. *Ribosomes (Incorrect)* - **Ribosomes** are responsible for **protein synthesis** (translation) based on mRNA templates. - They have no role in fatty acid metabolism.

Q: What is the primary defect associated with type II hyperlipidemia?

LDL receptor. ***LDL receptor*** - A defect in the **LDL receptor** leads to type II hyperlipidemia, characterized by elevated **LDL cholesterol** levels in the blood [1]. - This condition results in increased risk for **atherosclerosis** and cardiovascular diseases due to impaired cellular uptake of cholesterol [1,2]. *Apo-E* - Deficiencies of **Apo-E** typically result in type III hyperlipidemia, associated with **remnant lipoprotein clearance** issues rather than type II. - It affects metabolism of **chylomicron remnants** and intermediate density lipoproteins (IDL), not primarily LDL. *None* - This option incorrectly suggests that there is no defect associated with type II hyperlipidemia; in reality, it is primarily linked to **LDL receptor** dysfunction [1]. - The term "none" implies a lack of specific pathology, which is inaccurate in the context of hyperlipidemia types. *Lipoprotein lipase* - Deficiency in **lipoprotein lipase** leads to type I (or V) hyperlipidemia, characterized by increased **triglyceride** levels rather than just LDL. - It primarily impairs the hydrolysis of triglycerides in chylomicrons and VLDL, which differs from the LDL receptor's function [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 157-159. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 156-157.

Q: A child presents with bone pain and hepatosplenomegaly, indicative of Gaucher's disease. A trephine biopsy and aspirate show the following finding. Which of the following is the most likely enzyme deficient in this condition?

Glucocerebrosidase. ***Correct: Glucocerebrosidase*** - The clinical presentation of **bone pain**, **hepatosplenomegaly**, and the characteristic histological finding of **lipid-laden macrophages** (Gaucher cells) with a **crinkled paper** appearance in the bone marrow aspirate are highly suggestive of **Gaucher's disease**. - **Gaucher's disease** is caused by a deficiency of the lysosomal enzyme **glucocerebrosidase**, leading to the accumulation of **glucocerebroside**. *Incorrect: Hexosaminidase* - Deficiency of **hexosaminidase A** is associated with **Tay-Sachs disease**, which presents with neurological degeneration but typically **lacks hepatosplenomegaly** and bone pain. - The histological findings in Tay-Sachs disease would show neuronal storage of **GM2 gangliosides**, not Gaucher cells. *Incorrect: Sphingomyelinase* - Deficiency of **sphingomyelinase** causes **Niemann-Pick disease**, characterized by hepatosplenomegaly, neurological involvement, and interstitial lung disease, but the storage cells (foam cells) have a **foamy appearance** due to sphingomyelin accumulation, not the "crinkled paper" appearance of Gaucher cells. - While there is organomegaly, the distinct **histological features** in the image rule out Niemann-Pick disease. *Incorrect: Alpha 1,4-glucosidase* - Deficiency of **alpha 1,4-glucosidase** (acid maltase) causes **Pompe disease** (Glycogen Storage Disease Type II), which primarily affects muscle and liver with **glycogen accumulation**. - Pompe disease does not typically present with the same type of **bone pain** or the characteristic **Gaucher cells** seen in the image.

Question 1

All are true about beta oxidation of fatty acids except which of the following?

Accepted Answer

Carnitine Acyl transferase I is stimulated by malonyl CoA

Answer

Carnitine Acyl transferase I defect causes a decrease in acylcarnitine levels

Answer

Carnitine acyl transferase I is the rate limiting enzyme of fatty acid oxidation

Answer

Carnitine acyl transferase I is inhibited by malonyl CoA

Question 2

Which of the following statements about reverse cholesterol transport is false?

Accepted Answer

Lecithin Cholesterol Acyl Transferase helps in the conversion of Spheroidal HDL to Discoidal HDL.

Answer

Transport of cholesterol from extrahepatic tissues to liver.

Answer

Cholesterol Ester Transfer Protein reduces HDL levels.

Answer

ATP Binding Cassette Transporter protein is involved in the conversion of HDL3 to HDL2.

Question 3

Arachidonic acid oxidation involves how many cycles of beta oxidation?

Accepted Answer

9

Answer

20

Answer

8

Answer

10

Question 4

Refsum's disease is due to deficiency of which of the following enzyme?

Accepted Answer

Phytanic alpha oxidase

Answer

Thiophorase

Answer

Succinate thiokinase

Answer

Malonate dehydrogenase

Question 5

Which of the following conditions is characterized by a lack of genetically mediated VLDL overproduction?

Accepted Answer

Hypoapobetalipoproteinemia

Answer

Familial dyslipidemic hypertension

Answer

LDL subclass B

Answer

Familial combined hyperlipidemia

Question 6

In congenital adrenal hyperplasia, which enzyme deficiency is primarily responsible for precocious puberty in males?

Accepted Answer

21-hydroxylase deficiency

Answer

11-beta-hydroxylase deficiency

Answer

Both

Answer

Neither

Question 7

Rate limiting step in fatty acid synthesis is?

Accepted Answer

Production of malonyl-CoA

Answer

Production of acetyl CoA

Answer

Production of oxaloacetate

Answer

Production of citrate

Question 8

Oxidation of very long chain fatty acids takes place in ?

Accepted Answer

Peroxisomes

Answer

Ribosomes

Answer

Cytosol

Answer

Mitochondria

Question 9

What is the primary defect associated with type II hyperlipidemia?

Accepted Answer

LDL receptor

Answer

Apo-E

Answer

Lipoprotein lipase

Answer

HMG-CoA reductase

Question 10

A child presents with bone pain and hepatosplenomegaly, indicative of Gaucher's disease. A trephine biopsy and aspirate show the following finding. Which of the following is the most likely enzyme deficient in this condition?

Accepted Answer

Glucocerebrosidase

Answer

Hexosaminidase

Answer

Sphingomyelinase

Answer

Alpha 1,4-glucosidase

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?